FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2152160187> ?p ?o ?g. }

• W2152160187 endingPage "340" @default.
• W2152160187 startingPage "339" @default.
• W2152160187 abstract "From the meta-analysis by Lassemillante et al. [1] in this issue of the Journal, it is clear that there is a high prevalence of osteoporosis and low bone mass (osteopenia) by dual energy x-ray absorptiometry (DXA) in men treated with androgen deprivation therapy (ADT) for prostate cancer. While the prevalence of osteoporosis varied among the cited studies, there is no doubt that the impact of ADT on bone mineral density, and therefore, fracture risk is underappreciated by patients and medical professionals. ADT may include analogs of gonadotropin releasing hormone (GnRH), androgen receptor blockers, or a combination of the two. In the past and rarely today, orchiectomy has been used to lead to a hypogonadal state. It is important to note that the dramatic decrease of testosterone by GnRH analogs or orchiectomy also leads to very low levels of estradiol, which is of particular import for bone in older men [2]. Prostate cancer patients treated with only androgen receptor blockade have less loss of bone than those treated with GnRH analogs or combined therapy [3]. Lassemillante et al. [1] also comment on the addition of forearm bone density, usually the distal 1/3 radius, as an important measure of bone density in men on ADT. In older men, degenerative changes in the spine commonly prevent interpretation of bone density. In some studies [4, 5], an additional 15 % or more of patients are diagnosed with osteoporosis or low bone mass by the addition of radius bone density. This suggests that all older men on ADT should have forearm bone density done routinely. An additional method to identify ADT patients at risk for fracture would be to use the FRAX calculation. Saylor et al. [6] found that FRAX identified additional men at risk for fracture—beyond those found by DXA. In our own study [7] of 115 consecutive men on ADT, FRAX calculations with and without DXA produced different populations considered at risk for fracture. Finally, the International Society for Clinical Densitometry is now recommending that a white female database be used for calculating T-scores for men [8], which will lower the percentage of men with low bone mass and osteoporosis. The confusion from such varied results makes evaluation and treatment of men on ADT less likely. As pointed out by Lassemillante et al. [1], men on ADT may have sexual dysfunction, gynecomastia, and body composition changes that may increase the risk of metabolic syndrome. In addition, hot flashes/flushes and fatigue are common complaints in men on ADT. Thus, even though the risk of osteoporosis may be as high as 50 % and the risk of fracture after 5 years of ADT may be as high as 20 % [9], it is doubtful that the man on ADT will be concerned about the silent disorder osteoporosis. This is particularly disturbing because bisphosphonates [10, 11] and more recently denosumab [12] have been shown to improve bone mineral density and in the case of denosumab [12] decrease morphometric vertebral fractures. Toremefine [13], an estrogen agonist/antagonist has also been shown to decrease morphometric vertebral fractures in men on ADT. Hence, as in other causes of secondary osteoporosis in men, such as glucocorticoid-induced osteoporosis [14], little attention is paid to the high fracture risk despite the R. A. Adler (&) Endocrinology (111P), McGuire Veterans Affairs Medical Center, 1201 Broad Rock Boulevard, Richmond, VA 23249, USA e-mail: robert.adler@va.gov" @default.
• W2152160187 created "2016-06-24" @default.
• W2152160187 creator A5066281483 @default.
• W2152160187 date "2013-12-24" @default.
• W2152160187 modified "2023-09-27" @default.
• W2152160187 title "Prostate cancer treated with androgen deprivation therapy has consequences for bone" @default.
• W2152160187 cites W1480772894 @default.
• W2152160187 cites W1992053982 @default.
• W2152160187 cites W1993717188 @default.
• W2152160187 cites W1997732940 @default.
• W2152160187 cites W2025317506 @default.
• W2152160187 cites W2029332257 @default.
• W2152160187 cites W2045981419 @default.
• W2152160187 cites W2079604430 @default.
• W2152160187 cites W2088230452 @default.
• W2152160187 cites W2122204299 @default.
• W2152160187 cites W2128173189 @default.
• W2152160187 cites W2129550487 @default.
• W2152160187 cites W2156193065 @default.
• W2152160187 doi "https://doi.org/10.1007/s12020-013-0113-x" @default.
• W2152160187 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24366636" @default.
• W2152160187 hasPublicationYear "2013" @default.
• W2152160187 type Work @default.
• W2152160187 sameAs 2152160187 @default.
• W2152160187 citedByCount "1" @default.
• W2152160187 countsByYear W21521601872018 @default.
• W2152160187 crossrefType "journal-article" @default.
• W2152160187 hasAuthorship W2152160187A5066281483 @default.
• W2152160187 hasBestOaLocation W21521601871 @default.
• W2152160187 hasConcept C121608353 @default.
• W2152160187 hasConcept C126322002 @default.
• W2152160187 hasConcept C134018914 @default.
• W2152160187 hasConcept C143998085 @default.
• W2152160187 hasConcept C2776235491 @default.
• W2152160187 hasConcept C2777899217 @default.
• W2152160187 hasConcept C2777911890 @default.
• W2152160187 hasConcept C2780192828 @default.
• W2152160187 hasConcept C555293320 @default.
• W2152160187 hasConcept C71315377 @default.
• W2152160187 hasConcept C71924100 @default.
• W2152160187 hasConceptScore W2152160187C121608353 @default.
• W2152160187 hasConceptScore W2152160187C126322002 @default.
• W2152160187 hasConceptScore W2152160187C134018914 @default.
• W2152160187 hasConceptScore W2152160187C143998085 @default.
• W2152160187 hasConceptScore W2152160187C2776235491 @default.
• W2152160187 hasConceptScore W2152160187C2777899217 @default.
• W2152160187 hasConceptScore W2152160187C2777911890 @default.
• W2152160187 hasConceptScore W2152160187C2780192828 @default.
• W2152160187 hasConceptScore W2152160187C555293320 @default.
• W2152160187 hasConceptScore W2152160187C71315377 @default.
• W2152160187 hasConceptScore W2152160187C71924100 @default.
• W2152160187 hasIssue "3" @default.
• W2152160187 hasLocation W21521601871 @default.
• W2152160187 hasLocation W21521601872 @default.
• W2152160187 hasOpenAccess W2152160187 @default.
• W2152160187 hasPrimaryLocation W21521601871 @default.
• W2152160187 hasRelatedWork W198910458 @default.
• W2152160187 hasRelatedWork W1992510798 @default.
• W2152160187 hasRelatedWork W2004261902 @default.
• W2152160187 hasRelatedWork W2032616737 @default.
• W2152160187 hasRelatedWork W2127396703 @default.
• W2152160187 hasRelatedWork W2140855177 @default.
• W2152160187 hasRelatedWork W2150609534 @default.
• W2152160187 hasRelatedWork W2313974125 @default.
• W2152160187 hasRelatedWork W2501991984 @default.
• W2152160187 hasRelatedWork W3200282916 @default.
• W2152160187 hasVolume "45" @default.
• W2152160187 isParatext "false" @default.
• W2152160187 isRetracted "false" @default.
• W2152160187 magId "2152160187" @default.
• W2152160187 workType "article" @default.